Pfizer says the FDA has approved the company’s Lipitor (atorvastatin calcium) Tablets to reduce the risk of ...
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
Pfizer says the FDA has approved the company’s Lipitor (atorvastatin calcium) Tablets to reduce the risk of ...
March 22, 2007 — Pfizer says the FDA has approved the company’s Lipitor (atorvastatin calcium) Tablets to reduce the ...
Thyroid hormone has multiple effects on the cardiovascular system. These include increased cardiac contractility ...
March 9, 2007 — Pfizer has announced that the FDA has approved Lipitor (atorvastatin calcium) Tablets to reduce the risk ...
Feb. 6, 2007 — The FDA has issued an approval letter for GlaxoSmithKline’s once-a-day anticoagulant, Arixtra ...
iCardiac Technologies, Inc. and Pfizer have into a multiyear research alliance to develop and validate advanced ECG ...
Jan. 29, 2007 — Novadaq Technologies Inc. and Apple Inc. presented new technologies to about 100 heart surgeons Sunday ...
Jan. 25, 2007 — Research emerging this week from a Harvard researcher claims there is no evidence that statins prevent ...
Jan. 19, 2007 — Daiichi Sankyo Co., Ltd. and Eli Lilly and Co. have announced completion of patient enrollment in their ...
Jan 11, 2007 — FDA approval last week of Anthera’s Investigational New Drug (IND) application for its lead ...
Jan. 5, 2007 — An announcement from AstraZeneca is expected soon about the company’s experimental heart drug AGI ...
A review by physicians at Tulane University School of Public Health and Tropical Medicine shows that Vitamin B12 ...
Heartwire cites results of a new study finding that current heart-failure performance measures, with the exception of ...
Taking anti-platelet medication longer than current recommendations may lower heart attack or death risks for patients ...
The FDA was notified on Dec. 2 that Pfizer will suspend a large, Phase 3 trial evaluating the investigational ...